Literature DB >> 16769945

Measuring Friedreich ataxia: complementary features of examination and performance measures.

D R Lynch1, J M Farmer, A Y Tsou, S Perlman, S H Subramony, C M Gomez, T Ashizawa, G R Wilmot, R B Wilson, L J Balcer.   

Abstract

OBJECTIVE: To examine the potential validity of performance measures and examination-based scales in Friedreich ataxia (FA) by examining their correlation with disease characteristics.
METHODS: The authors assessed the properties of a candidate clinical outcome measure, the Friedreich Ataxia Rating Scale (FARS), and simple performance measures (9-hole peg test, the timed 25-foot walk, PATA test, and low-contrast letter acuity) in 155 patients with FA from six institutions, and correlated the scores with disease duration, functional disability, activity of daily living scores, age, and shorter GAA repeat length to assess whether these measures capture the severity of neurologic dysfunction in FA.
RESULTS: Scores for the FARS and performance measures correlated significantly with functional disability, activities of daily living scores, and disease duration, showing that these measures meet essential criteria for construct validity for measuring the progressive nature of FA. In addition, the FARS and transformed performance measures scores were predicted by age and shorter GAA repeat length in linear regression models accounting for sex and testing site. Correlations between performance measures were moderate in magnitude, suggesting that each test captures separate yet related dimensions of neurologic function in FA and that a composite measure might better predict disease status. Composite measures created using cohort means and standard deviations predicted disease status better than or equal to single performance measures or examination-based measures.
CONCLUSIONS: The Friedreich Ataxia Rating Scale, performance measures, and performance measure composites provide valid assessments of disease progression in Friedreich ataxia.

Entities:  

Mesh:

Year:  2006        PMID: 16769945     DOI: 10.1212/01.wnl.0000218155.46739.90

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  56 in total

1.  Longitudinal change in dysarthria associated with Friedreich ataxia: a potential clinical endpoint.

Authors:  Kristin M Rosen; Joanne E Folker; Adam P Vogel; Louise A Corben; Bruce E Murdoch; Martin B Delatycki
Journal:  J Neurol       Date:  2012-06-06       Impact factor: 4.849

2.  Antioxidant use in Friedreich ataxia.

Authors:  Lauren Myers; Jennifer M Farmer; Robert B Wilson; Lisa Friedman; Amy Tsou; Susan L Perlman; Sub H Subramony; Christopher M Gomez; Tetsuo Ashizawa; George R Wilmot; Katherine D Mathews; Laura J Balcer; David R Lynch
Journal:  J Neurol Sci       Date:  2007-11-07       Impact factor: 3.181

3.  Mortality in Friedreich's Ataxia.

Authors:  David R Lynch; Jennifer M Farmer; Robert B Wilson
Journal:  Tex Heart Inst J       Date:  2007

4.  White matter changes in patients with friedreich ataxia after treatment with erythropoietin.

Authors:  Karl Egger; Christian Clemm von Hohenberg; Michael F Schocke; Charles R G Guttmann; Demian Wassermann; Marlene C Wigand; Wolfgang Nachbauer; Christian Kremser; Brigitte Sturm; Barbara Scheiber-Mojdehkar; Marek Kubicki; Martha E Shenton; Sylvia Boesch
Journal:  J Neuroimaging       Date:  2013-09-09       Impact factor: 2.486

5.  Eye Movement Abnormalities Are Ubiquitous in the Spinocerebellar Ataxias.

Authors:  Christopher D Stephen; Jeremy D Schmahmann
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

6.  An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Authors:  Eppie M Yiu; Geneieve Tai; Roger E Peverill; Katherine J Lee; Kevin D Croft; Trevor A Mori; Barbara Scheiber-Mojdehkar; Brigitte Sturm; Monika Praschberger; Adam P Vogel; Gary Rance; Sarah E M Stephenson; Joseph P Sarsero; Creina Stockley; Chung-Yung J Lee; Andrew Churchyard; Marguerite V Evans-Galea; Monique M Ryan; Paul J Lockhart; Louise A Corben; Martin B Delatycki
Journal:  J Neurol       Date:  2015-04-07       Impact factor: 4.849

7.  Common data elements for clinical research in Friedreich's ataxia.

Authors:  David R Lynch; Massimo Pandolfo; Jorg B Schulz; Susan Perlman; Martin B Delatycki; R Mark Payne; Robert Shaddy; Kenneth H Fischbeck; Jennifer Farmer; Paul Kantor; Subha V Raman; Lisa Hunegs; Joanne Odenkirchen; Kristy Miller; Petra Kaufmann
Journal:  Mov Disord       Date:  2012-12-12       Impact factor: 10.338

8.  Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia.

Authors:  Giovanni Coppola; Daniele Marmolino; Daning Lu; Qing Wang; Miriam Cnop; Myriam Rai; Fabio Acquaviva; Sergio Cocozza; Massimo Pandolfo; Daniel H Geschwind
Journal:  Hum Mol Genet       Date:  2009-04-17       Impact factor: 6.150

Review 9.  Evaluating the progression of Friedreich ataxia and its treatment.

Authors:  Martin B Delatycki
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

10.  Analysis of the visual system in Friedreich ataxia.

Authors:  Lauren A Seyer; Kristin Galetta; James Wilson; Reiko Sakai; Susan Perlman; Katherine Mathews; George R Wilmot; Christopher M Gomez; Bernard Ravina; Theresa Zesiewicz; Khalaf O Bushara; S H Subramony; Tetsuo Ashizawa; Martin B Delatycki; Alicia Brocht; Laura J Balcer; David R Lynch
Journal:  J Neurol       Date:  2013-06-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.